Insight
Lung Cancer Europe
Photo: depositphotos.com

NSCLC treated with EGFR inhibitors – EGFR Resisters

EGFR Resisters shared a post on X about a recent paper by Otto Manninen et al. published in Oncology:

“NSCLC treated with EGFR inhibitors: the effect of concurrent medications on patient outcomes

‘Conclusions: Among EGFR-TKI-treated NSCLC, the use of TCN, TCS, and DARD can affect treatment outcomes that should be considered in optimal patient care.’ ”

“Non-small cell lung cancer treated with epidermal growth factor receptor inhibitors: the effect of concurrent medications on patient outcomes”

Authors: Otto Manninen, Sanna Iivanainen, Martti Arffman, Jussi Pekka Koivunen.

NSCLC treated with EGFR inhibitors - EGFR Resisters

More posts featuring EGFR Resisters.

cancer EGFR inhibitors EGFR Resisters Jussi Pekka Koivunen Martti Arffman non small cell lung cancer NSCLC OncoDaily Oncology Otto Manninen Sanna Iivanainen